Sodium–glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, have demonstrated substantial benefits in heart failure, chronic kidney disease, and atherosclerotic cardiovascular disease, irrespective of diabetic status. Here, SLC5A2 is linked to heart failure.